JP Morgan Chase’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

JP Morgan Chase’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-129	Closed	-$1K	–	7241
2022 Q1	$1K	Buy	+129	New	+$1.57K	﹤0.01%	6527
2021 Q2	–	Sell	-1	Closed	–	–	6851
2021 Q1	$0	Hold	1	–	–	﹤0.01%	6574
2020 Q4	$0	Buy	+1	New	+$108	﹤0.01%	6155
2019 Q4	–	Sell	-1,773	Closed	-$886K	–	6012
2019 Q3	$886K	Buy	1,773 +478	+37%	+$270K	﹤0.01%	3901
2019 Q2	$719K	Buy	1,295 +623	+93%	+$382K	﹤0.01%	4041
2019 Q1	$410K	Buy	672 +84	+14%	+$45.8K	﹤0.01%	4302
2018 Q4	$215K	Sell	588 -51	-8%	-$27.4K	﹤0.01%	4573
2018 Q3	$431K	Buy	+639	New	+$453K	﹤0.01%	4347
2018 Q2	–	Sell	-100	Closed	-$126K	–	5780
2018 Q1	$126K	Buy	100 +62	+163%	+$91.7K	﹤0.01%	4519
2017 Q4	$57K	Buy	+38	New	+$60.1K	﹤0.01%	4854

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

JP Morgan Chase's NBRV Position: Q2 2022 in Review

JP Morgan Chase sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q2 2022, closing a stake of 129 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in NBRV in Q4 2017 and held it in 10 quarters. The position peaked at $886K in Q3 2019. 25 funds tracked by Wall St. Rank hold NBRV as of Q2 2022.

JP Morgan Chase reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q2 2022 after selling out during the quarter.
JP Morgan Chase sold 129 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q2 2022, an estimated $1K.
JP Morgan Chase first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q4 2017 and held it in 10 quarters.
JP Morgan Chase's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $886K in Q3 2019.
25 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q2 2022.

Based on JP Morgan Chase's 13F filing for Q2 2022, filed 11 Aug 2022.